Apply for Pfizer Grant for Generic JAK Inhibitors in Rheumatology 2026 (Up to $100,000 in Funding)

Application Deadline: 21 May 2026

About the Grant

The Pfizer Grant for Generic JAK Inhibitors in Rheumatology is designed to help healthcare professionals better understand how treatment pathways may change as generic JAK inhibitors enter the U.S. market in 2026, and how current evidence can inform safe, effective, and data-driven patient care. As the first generic versions of Janus kinase (JAK) inhibitors are expected to become available in the United States during 2026, this represents a significant shift in the treatment landscape for rheumatoid arthritis and other rheumatic conditions. Healthcare providers will need to navigate new considerations around treatment selection, patient monitoring, and integration of generic options into existing care pathways. This grant supports educational and quality improvement initiatives that address these evolving needs.

Grant Benefits

Funding Amount: Up to $100,000 USD per project

Project Duration: Maximum 12 months

The grant supports independent educational initiatives that help healthcare professionals understand:

• The anticipated changes in treatment pathways as generic JAK inhibitors become available
• How current clinical evidence can guide safe and effective use of both branded and generic JAK inhibitors
• Strategies for incorporating generic options into patient care while maintaining quality outcomes
• Best practices for patient selection, monitoring, and treatment optimization

Eligibility Requirements

This funding opportunity is intended for organizations, not individuals. Eligible applicants must be organizations that play a central role in healthcare education, quality improvement, or continuing medical education.

Eligible Applicants Include:

• Healthcare institutions such as hospitals, health systems, and academic medical centers
• Professional medical societies representing rheumatologists and other relevant specialties
• Medical education companies that develop and deliver continuing medical education (CME) and continuing education (CE) programs
• Other organizations involved in healthcare education, continuing medical education, quality improvement, or healthcare performance improvement

Core Eligibility Requirements:

To be eligible, the applicant organization must:

• Play a central role in the proposed project (not merely serving as a pass-through entity)
• Be legally able to receive funding directly from Pfizer Inc.
• Be responsible for project delivery and oversight throughout the grant period
• Have the organizational capacity to implement an independent educational initiative with appropriate governance, faculty, and evaluation mechanisms

Important Note: Individual healthcare professionals, including physicians, nurses, and other practitioners, are not eligible to apply directly. Individuals interested in participating in grant-funded projects should connect with eligible organizations that can serve as applicants.

Why This Grant Matters

The introduction of generic JAK inhibitors represents a significant change in the rheumatoid arthritis treatment landscape. While generic medications can improve access and reduce healthcare costs, they also raise important questions for clinicians:

• How do efficacy and safety profiles compare between branded and generic formulations?
• What considerations should guide treatment selection for individual patients?
• How should monitoring protocols be adapted when switching patients to generic options?
• What educational resources are needed to support informed prescribing decisions?

This grant supports the development of educational and quality improvement initiatives that address these questions, helping healthcare professionals navigate this transition while maintaining high standards of patient care. By investing in education and quality improvement, Pfizer aims to support the rheumatology community in optimizing outcomes for patients with rheumatic diseases.

Project Focus Areas

Proposed projects should address the educational needs of healthcare professionals related to the introduction of generic JAK inhibitors. Priority may be given to initiatives that:

• Develop educational resources to help clinicians understand the clinical and economic implications of generic JAK inhibitor availability
• Create tools or frameworks for integrating generic JAK inhibitors into treatment algorithms and care pathways
• Address gaps in knowledge about patient selection, safety monitoring, and management of JAK inhibitor therapy
• Support quality improvement initiatives that measure and optimize outcomes related to JAK inhibitor use
• Provide continuing medical education (CME) or continuing education (CE) activities that meet accreditation standards
• Facilitate multidisciplinary collaboration between rheumatologists, pharmacists, and other healthcare team members

Application Process

Click on the link to the application website to apply. The application should include:

• Organizational information and legal documentation
• Detailed project description, including objectives, target audience, and educational format
• Project timeline with key milestones
• Detailed budget and budget narrative
• Evaluation plan demonstrating how project outcomes will be measured
• Information about project leadership, faculty, and organizational oversight

Click here to apply

For More Information: Visit the Official Webpage of the Pfizer Grant for Generic JAK Inhibitors in Rheumatology